FDA approves Sanofi’s short-acting insulin lispro injection

The FDA today approved Sanofi‘s (NYSE:SNY) Admelog insulin lispro injection. The product is indicated to help adults and kids with Type I and Type II diabetes control their blood sugar levels.

Admelog is the first short-acting insulin approved using the FDA’s 505(b)(2) pathway.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves Sanofi’s short-acting insulin lispro injection appeared first on MassDevice.

from MassDevice http://ift.tt/2AM6TNg